
During a live event, Robert Orlowski, MD, PhD, and participants discussed selinexor combinations, dosing, and nausea prevention for an older patient with late relapsed multiple myeloma who declines CAR T.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Ready for the challenge? Let’s begin!
Question 1 of 4: What recent status did fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) receive from the FDA?






